Galera Therapeutics, Inc. (GRTX)
OTCMKTS · Delayed Price · Currency is USD
0.0230
-0.0020 (-8.00%)
Apr 29, 2025, 2:15 PM EDT

Galera Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Selling, General & Admin
1122.8420.2120.9515.71
Upgrade
Research & Development
3.1524.1231.0152.4254.85
Upgrade
Operating Expenses
14.1546.9551.2373.3770.55
Upgrade
Operating Income
-14.15-46.95-51.23-73.37-70.55
Upgrade
Interest Expense
--11.41-11.57-7.19-4.88
Upgrade
Interest & Investment Income
0.551.60.510.031.17
Upgrade
Currency Exchange Gain (Loss)
-0.01-0-0-00.03
Upgrade
Other Non Operating Income (Expenses)
0.45----
Upgrade
EBT Excluding Unusual Items
-13.15-56.77-62.29-80.53-74.23
Upgrade
Merger & Restructuring Charges
--2.31---
Upgrade
Impairment of Goodwill
-0.88----
Upgrade
Asset Writedown
-2.26----
Upgrade
Legal Settlements
0.98----
Upgrade
Pretax Income
-19.16-59.08-62.29-80.53-74.23
Upgrade
Income Tax Expense
-0.2--0.07--0.02
Upgrade
Net Income
-18.96-59.08-62.22-80.53-74.22
Upgrade
Net Income to Common
-18.96-59.08-62.22-80.53-74.22
Upgrade
Shares Outstanding (Basic)
5545272625
Upgrade
Shares Outstanding (Diluted)
5545272625
Upgrade
Shares Change (YoY)
22.63%64.47%5.03%3.70%586.06%
Upgrade
EPS (Basic)
-0.35-1.33-2.30-3.12-2.98
Upgrade
EPS (Diluted)
-0.35-1.33-2.30-3.12-2.98
Upgrade
Free Cash Flow
-12.15-44.91-43.45-68.24-59.99
Upgrade
Free Cash Flow Per Share
-0.22-1.01-1.60-2.65-2.41
Upgrade
EBITDA
-14.13-46.69-51.11-72.59-70.19
Upgrade
D&A For EBITDA
0.020.260.110.780.37
Upgrade
EBIT
-14.15-46.95-51.23-73.37-70.55
Upgrade
Updated Dec 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.